Effects of rivaroxaban: A Synthesis of Findings from 26 Studies

  1. Home
  2. Effects of rivaroxaban
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of rivaroxaban: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of rivaroxaban: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major findings

Rivaroxaban is a new type of blood thinner that is used to prevent and treat blood clots. 14 found that apixaban has equivalent efficacy in preventing recurrent VTE but a decreased risk of major and minor bleeding events compared with rivaroxaban. 24 shows that rivaroxaban has anticoagulant effects in dogs. 19 suggests that rivaroxaban may affect the differentiation ability of endothelial progenitor cells, which play roles in vascular injury repair and atherogenesis. 13 found that rivaroxaban plus aspirin significantly reduced strokes compared with aspirin alone in patients with atrial fibrillation. 15 suggests that rivaroxaban may have protective effects on white matter integrity and remyelination in a mouse model of Alzheimer's disease.

Benefits and risks

Benefit summary

Rivaroxaban is an effective drug for preventing and treating blood clots. 6 found that rivaroxaban is associated with a significant decrease in fatal bleeding compared with vitamin K antagonists. Rivaroxaban is also effective in preventing blood clots after surgery. 4 found that apixaban was associated with significantly fewer major bleeding events after knee arthroplasty. Rivaroxaban can be used safely with antiplatelet drugs. 5 found that rivaroxaban is safe to use with antiplatelet drugs. Rivaroxaban has fewer drug interactions and does not require monitoring, making it more convenient for patients. 7 found that rivaroxaban reduced the risk of stroke or systemic embolism without significantly increasing the safety concern compared with warfarin. Rivaroxaban may also reduce the risk of cardiovascular events, such as stroke. 13 found that rivaroxaban plus aspirin significantly reduced strokes compared with aspirin alone in patients with atrial fibrillation.

Risk summary

Rivaroxaban can increase the risk of bleeding. 6 found that rivaroxaban is associated with a significant decrease in fatal bleeding compared with vitamin K antagonists. Rivaroxaban can increase the risk of bleeding in patients with kidney problems. 3 found that rivaroxaban and dabigatran show significant age-dependent renal accumulation. Rivaroxaban can interact with other drugs. 1 found that there is no clinically relevant interaction between rivaroxaban and aspirin.

Comparison between studies

Similarities

Many studies show that rivaroxaban is an effective drug for preventing and treating blood clots. Many studies also show that rivaroxaban has a lower risk of bleeding than warfarin.

Differences

A study that compared the effects and safety of rivaroxaban and apixaban found that apixaban has a greater anticoagulant effect than rivaroxaban. 14 found that apixaban has equivalent efficacy in preventing recurrent VTE but a decreased risk of major and minor bleeding events compared with rivaroxaban.

Consistency and contradictions in the results

Many studies show that rivaroxaban is an effective drug for preventing and treating blood clots. However, many studies also show that rivaroxaban can increase the risk of bleeding. Rivaroxaban can increase the risk of bleeding in patients with kidney problems. 3 found that rivaroxaban and dabigatran show significant age-dependent renal accumulation. Rivaroxaban can interact with other drugs. 1 found that there is no clinically relevant interaction between rivaroxaban and aspirin.

Things to keep in mind when applying the results to real life

Rivaroxaban is an effective drug for preventing and treating blood clots. However, rivaroxaban can increase the risk of bleeding, so it is important to take it as directed by your doctor. If you have kidney problems or are taking other medications, talk to your doctor before taking rivaroxaban. If you are going to have surgery, talk to your doctor about rivaroxaban before the surgery.

Limitations of current research

Rivaroxaban is a new drug, so its long-term safety and effectiveness are still being studied. Rivaroxaban does not work for everyone. Rivaroxaban can interact with other drugs. It is important to talk to your doctor before taking rivaroxaban.

Future research directions

Rivaroxaban is a new drug, and its long-term safety and effectiveness are still being studied. Further research is needed to evaluate its long-term safety and effectiveness. Rivaroxaban does not work for everyone. Further research is needed to identify the characteristics of patients who will benefit from rivaroxaban. Rivaroxaban can interact with other drugs. Further research is needed to evaluate the interaction of rivaroxaban with other drugs.

Conclusion

Rivaroxaban is an effective drug for preventing and treating blood clots. However, rivaroxaban can increase the risk of bleeding, so it is important to take it as directed by your doctor. Talk to your doctor before taking rivaroxaban. Rivaroxaban is a new drug, and its long-term safety and effectiveness are still being studied. Further research is needed to evaluate its long-term safety and effectiveness.

Literature analysis of 26 papers
Positive Content
25
Neutral Content
0
Negative Content
1
Article Type
9
5
2
2
25
1.

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.

Author: KubitzaDagmar, BeckaMichael, MueckWolfgang, ZuehlsdorfMichael

Can be administered together
No interaction with aspirin

Rivaroxaban, an oral Factor Xa inhibitor, is safe and effective for preventing and treating thromboembolic disorders. A study found that aspirin did not significantly impact the safety, tolerability, pharmacodynamics, or pharmacokinetics of rivaroxaban. Therefore, the two drugs can be administered concurrently at the doses used in the study.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.

Author: KubitzaDagmar, MueckWolfgang, BeckaMichael

blood clotting prevention
thromboembolic disorders
arrhythmia

Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor being developed for the prevention and treatment of thromboembolic disorders. Pro-arrhythmic effects are a common reason for drugs failing to gain regulatory approval, so the effect of rivaroxaban on the QT interval was assessed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.

Author: WelzelD, HullR, FareedJ

Thromboembolism prevention
Bleeding risk

Newer therapeutic options for preventing postoperative thromboembolism, including fondaparinux, rivaroxaban, and dabigatran, are being compared to enoxaparin. These newer options have shown promise in clinical trials, but they are associated with an increased risk of bleeding.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.

Author: AlvesCarlos, Batel-MarquesFrancisco, MacedoAna Filipa

Reduced bleeding

A meta-analysis compared the safety of apixaban and rivaroxaban, two direct Xa coagulation factor inhibitors, in patients undergoing knee and hip arthroplasty. Apixaban was associated with fewer major and total bleeding events after knee arthroplasty compared to rivaroxaban, with no significant differences observed after hip arthroplasty.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.

Author: ErikssonBengt I, RosencherNadia, FriedmanRichard J, HomeringMartin, DahlOla E

Thromboembolism prevention
Postoperative bleeding

This analysis compared the safety of concomitant use of specified medications with rivaroxaban and enoxaparin in the RECORD programme, which compared oral rivaroxaban with enoxaparin for prevention of venous thromboembolism after elective total hip or knee replacement.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Meta-analysis of rivaroxaban and bleeding risk.

Author: WasserlaufGuila, GrandiSonia M, FilionKristian B, EisenbergMark J

Bleeding risk reduction

This meta-analysis of five randomized controlled trials comparing rivaroxaban to vitamin K antagonists for stroke prevention, deep vein thrombosis, and pulmonary embolism found that rivaroxaban was not associated with an increased risk of bleeding overall. However, it was associated with a significant decrease in fatal bleeding.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.

Author: MaoLizheng, LiChengyan, LiTao, YuanKunxiong

Embolism reduction
Stroke reduction
Bleeding risk

Rivaroxaban effectively reduced the risk of stroke or systemic embolism in Chinese patients with atrial fibrillation without significantly increasing bleeding risks.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

8.

A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.

Author: SairakuAkinori, YoshidaYukihiko, AndoMonami, HirayamaHaruo, NakanoYukiko, KiharaYasuki

No need for anticoagulation monitoring
Increased risk of hypercoagulability

Rivaroxaban may increase the risk of hypercoagulability when used during the periprocedural period of atrial fibrillation (AF) ablation compared with dabigatran.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Safety and efficacy of rivaroxaban versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a meta-analysis of observational studies.

Author: LiWentao, GaoChuanyu, LiMuwei, WangXianpei, QiDatun, ZhangYou, HaoPeiyuan, LiuJun, ZhuLijie

Major bleeding reduction
Thromboembolic event reduction

This meta-analysis suggests that patients treated with rivaroxaban have a similar incidence of thromboembolic events and major bleeding compared to warfarin.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

10.

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Author: SamuelsonBethany T, CukerAdam, SiegalDeborah M, CrowtherMark, GarciaDavid A

Treatment of choice for atrial fibrillation
Treatment of choice for venous thromboembolic disease

Direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or noncancer-associated venous thromboembolic disease. This review summarizes systematically evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban, and edoxaban.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

11.

Anticoagulant activity of oral rivaroxaban in healthy dogs.

Author: ConversyB, BlaisM C, DunnM, Gara-BoivinC, Del CastilloJ R E

Thrombotic disorders

This study evaluated the anticoagulant effects of rivaroxaban, a direct factor Xa inhibitor, in healthy dogs. Rivaroxaban was found to have a concentration-dependent anticoagulant effect that lasted for 24 hours when administered twice daily. The study suggests that rivaroxaban could be a potential therapeutic option for dogs with thrombotic disorders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

12.

Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.

Author: KreutzR, PerssonP B, KubitzaD, ThelenK, HeitmeierS, SchwersS, BeckaM, HemmrichM

Prolonged anticoagulation

This study compared the effects of rivaroxaban and apixaban, two drugs used to prevent blood clots. The study found that rivaroxaban was more effective at preventing blood clots.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Stroke Outcomes in the COMPASS Trial.

Author: SharmaMukul, HartRobert G, ConnollyStuart J, BoschJackie, ShestakovskaOlga, NgKelvin K H, CataneseLuciana, KeltaiKatalin, AboyansVictor, AlingsMarco, HaJong-Won, VarigosJohn, TonkinAndrew, O'DonnellMartin, BhattDeepak L, FoxKeith, MaggioniAldo, BerkowitzScott D, BrunsNancy Cook, YusufSalim, EikelboomJohn W

Stroke prevention

The COMPASS trial showed that combining rivaroxaban with aspirin reduced the risk of stroke compared to aspirin alone. This analysis delves into the types of strokes observed, predictors, and antithrombotic effects in various patient subgroups.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.

Author: AryalMadan Raj, GosainRohit, DonatoAnthony, YuHan, KatelAnjan, BhandariYashoda, DhitalRashmi, KouidesPeter A

Equivalent efficacy
Reduced bleeding

Apixaban and rivaroxaban are anticoagulants used for acute venous thromboembolism (VTE). A meta-analysis of real-world studies found that apixaban was equally effective in preventing recurrent VTE but had a lower risk of major and minor bleeding compared to rivaroxaban.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

16.

Effects of rivaroxaban on myocardial mitophagy in the rat heart.

Author: GencpinarTugra, BilenCagatay, KemahliBaris, KacarKivanc, AkokayPinar, BayrakSerdar, ErdalCenk

Cardiomyocyte protection
Reduced heart damage

Rivaroxaban may have reduced cell death in cardiomyocytes during myocardial infarction and thus have reduced damage to the heart tissue caused by myocardial infarction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.

Author: SharmaAbhinav, CaldeiraDaniel, RazaghizadAmir, PintoFausto J, van VeldhuisenDirk J, MehraMandeep R, LamCarolyn S P, ClelandJohn, AnkerStefan D, GreenbergBarry, FerreiraJoao Pedro, ZannadFaiez

Heart failure treatment

Rivaroxaban, a direct oral anticoagulant, was compared to placebo in a randomized trial of patients hospitalized for worsening heart failure with coronary artery disease. The study aimed to assess the effects of rivaroxaban on cardiovascular events in patients with diabetes.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells.

Author: SohmaRyoichi, SakumaMasashi, ObiSyotaro, NishinoSetsu, InoueKen-Ichi, KishimotoSatoko, LuTianyang, ToyodaShigeru, InoueTeruo

Vascular injury repair
Atherogenesis

This study evaluates the effect of the factor Xa inhibitor rivaroxaban on the differentiation ability of vascular endothelial progenitor cells (EPCs). Antithrombotic treatment in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) is challenging, and this study aims to provide further biological evidence for the pharmacological effects of anticoagulants.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Negative effects of rivaroxaban observed in a patient with multiple common risks triggered by a bicycle accident.

Author: AbeKurumi, MomoKenji, OtoYuji, KidaMasaki, IwakiriTakuma, TanakaKatsumi, SasakiTadanori

Anticoagulant side effects

Anticoagulants have known negative effects in patients with kidney problems, drug interactions, and other health issues. This paper highlights that even in patients with controllable risks for rivaroxaban use, added risks can lead to greater negative effects.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

23.

Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study.

Author: TakaiShigeki, NakanishiNaohiko, YokotaIsao, ImaiKojiro, YamadaAyumu, KawasakiTakanori, KasaharaTakeru, OkadaTakashi, SawadaTakahisa, MatobaSatoaki

Clot regression
Bleeding

This study investigates the clot regression effects of rivaroxaban, a direct oral anticoagulant, in patients with cancer-associated venous thromboembolism (CAT). The results show that rivaroxaban significantly reduced clot volume and achieved a high clot-regression rate, suggesting its efficacy in treating CAT. However, the study also highlights the importance of monitoring for bleeding complications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.